Cellular delivery of antisense oligonucleotides

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 50, Issue 1, 2000, Pages 101-119

  Lebedeva, Irina ^a   Benimetskaya, Lyuba ^a   Stein, C A ^a   Vilenchik, Maria ^a  

^a Columbia University ^*  (United States)

Author keywords

Antisense oligonucleotides; Cationic lipids; Delivery; Dendrimers; In vivo delivery; Peptide oligonucleotide conjugates

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DENDRIMER; DNA; DRUG CARRIER; LIPID; LIPOSOME; PEPTIDE; PROTEIN;

DRUG DELIVERY SYSTEM; GENE TARGETING; MACROMOLECULE; REVIEW;

ANIMALS; CELLS; HUMANS; LIPOSOMES; OLIGONUCLEOTIDES, ANTISENSE; VEHICLES;

EID: 0034601112     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(00)00088-6     Document Type: Review

References (255)

1. Stein C.A., Cheng Y.C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science. 261:1993;1004-1012.
2. Wagner R.W. Gene inhibition using antisense oligonucleotides. Nature. 372:1994;333-335.
3. McKay R.A., Miraglia L.J., Cummins L.L., Owens S.R., Sasmor H., Dean N.M. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J. Biol. Chem. 274:1999;1715-1722.
4. Monia B.P., Sasmor H., Johnston J.F., Freier S.M., Lesnik E.A., Muller M., Geiger T., Altmann K.H., Moser H., Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;15481-15484.
5. Vaerman J.L., Moureau P., Deldime F., Lewalle P., Lammineur C., Morschhauser F., Martiat P. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood. 90:1997;331-339.
6. E. Gendaszewska, M. Maszewska, M. Koziolkiewicz, C.A. Stein W. Stec, On the cytotoxicity of mononucleotides, (2000) in preparation.
7. Stec W.J., Zon G., Egan W., Stec B. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106:1984;6077-6080.
8. Stec W.J., Wilk A. Stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s. Angew. Chem. Int. Ed. Engl. 33:1994;709-722.
9. Agrawal S., Zhao Q. Antisense therapeutics. Curr. Opin. Chem. Biol. 2:1998;519-528.
10. Yuen A.R., Halsey J., Fisher G.A., Holmlund J.T., Geary R.S., Kwoh T.J., Dorr A., Sikic B.I. Phase I study of an antisense oligonucleotide to protein kinase C-((ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5:1999;3357-3363.
11. Anderson K.P., Fox M.C., Brown-Driver V., Martin M.J., Azad R.F. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40:1996;2004-2011.
12. Shoji Y., Akhtar S., Periasamy A., Herman B., Juliano R.L. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 19:1991;5543-5550.
13. Guvakova M.A., Yakubov L.A., Vlodavsky I., Tonkinson J.L., Stein C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270:1995;2620-2627.
14. Fennewald S.M., Rando R.F. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J. Biol. Chem. 270:1995;21718-21721.
15. Rockwell P., O'Connor W.J., King K., Goldstein N.I., Zhang L.M., Stein C.A. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 94:1997;6523-6528.
16. Benimetskaya L., Loike J.D., Khaled Z., Loike G., Silverstein S.C., Cao L., el Khoury J., Cai T.Q., Stein C.A. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. (see comments) Nat. Med. 3:1997;414-420.
17. Wu-Pong S., Weiss T.L., Hunt C.A. Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res. Dev. 4:1994;155-163.
18. Hawley P., Gibson I. Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev. 6:1996;185-195.
19. Goodarzi G., Watabe M., Watabe K. Binding of oligonucleotides to cell membranes at acidic pH. Biochem. Biophys. Res. Commun. 181:1991;1343-1351.
20. Gasparro F.P., Dall'Amico R., O'Malley M., Heald P.W., Edelson R.L. Cell membrane DNA: a new target for psoralen photoadduct formation. Photochem. Photobiol. 52:1990;315-321.
21. Beltinger C., Saragovi H.U., Smith R.M., LeSauteur L., Shah N., DeDionisio L., Christensen L., Raible A., Jarett L., Gewirtz A.M. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95:1995;1814-1823.
22. Yao G.Q., Corrias S., Cheng Y.C. Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. Biochem. Pharmacol. 51:1996;431-436.
23. Benimetskaya L., Tonkinson J.L., Koziolkiewicz M., Karwowski B., Guga P., Zeltser R., Stec W., Stein C.A. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res. 23:1995;4239-4245.
24. Yakubov L.A., Deeva E.A., Zarytova V.F., Ivanova E.M., Ryte A.S., Yurchenko L.V., Vlassov V.V. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA. 86:1989;6454-6458.
25. Crooke R.M., Graham M.J., Cooke M.E., Crooke S.T. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275:1995;462-473.
26. Stein C.A., Tonkinson J.L., Zhang L.M., Yakubov L., Gervasoni J., Taub R., Rotenberg S.A. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry. 32:1993;4855-4861.
27. Summerton J., Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7:1997;187-195.
28. Bergan R., Hakim F., Schwartz G.N., Kyle E., Cepada R., Szabo J.M., Fowler D., Gress R., Neckers L. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood. 88:1996;731-741.
29. Giles R.V., Spiller D.G., Tidd D.M. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5:1995;23-31.
30. Ljungstrom T., Knudsen H., Nielsen P.E. Cellular uptake of adamantyl conjugated peptide nucleic acids. Bioconjug. Chem. 10:1999;965-972.
31. Tonkinson J.L., Stein C.A. Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. 22:1994;4268-4275.
32. Fisher T.L., Terhorst T., Cao X., Wagner R.W. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res. 21:1993;3857-3865.
33. Moulds C., Lewis J.G., Froehler B.C., Grant D., Huang T., Milligan J.F., Matteucci M.D., Wagner R.W. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry. 34:1995;5044-5053.
34. Anfossi G., Gewirtz A.M., Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA. 86:1989;3379-3383.
35. Gewirtz A.M., Calabretta B. c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science. 242:1988;1303-1306.
36. Wyatt J.R., Davis P.W., Freier S.M. Kinetics of G-quartet-mediated tetramer formation. Biochemistry. 35:1996;8002-8008.
37. McCarthy M.M. Modulating Gene Expression by Antisense Oligonucleotides to Understand Neural Functioning. 1998;Kluwer Academic Publishers, Dordrecht.
38. Dean N.M., McKay R. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 91:1994;11762-11766.
39. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M., Wolff K., Eichler H.G., Pehamberger H. bcl-2 Antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4:1998;232-234.
40. Nyce J.W., Metzger W.J. DNA antisense therapy for asthma in an animal model. (see comments) published erratum appears in Nature, 390(6658) (1997) 424 Nature. 385:1997;721-725.
41. Metzger W.J., Nyce J.W. Respirable antisense oligonucleotide (RASON) therapy for allergic asthma. BioDrug. 12:1999;237-243.
42. Sessa G., Weissmann G. Phospholipids spherules (liposomes) as a model for biological membranes. J. Lipid Res. 9:1968;310-318.
43. Szoka F., Papahadjopoulos D. Comparative properties and methods in preparation of lipid vesicles. Annu. Rev. Biophys. Bioeng. 9:1990;467-508.
44. Cullis P.R., Mayer L.D., Bally M.B., Madden T.D., Hope M.J. Generating and loading of liposomal systems for drug delivery applications. Adv. Drug Deliv. Rev. 3:1989;267-282.
45. Hope M.J., Mui B., Ansell S., Ahkong Q.F. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs. (review) Mol. Membr. Biol. 15:1998;1-14.
46. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA. 84:1987;7413-7417.
47. Wrobel I., Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim. Biophys. Acta. 1235:1995;296-304.
48. Hong K., Zeng W., Baker A., Papahadjopoulos D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo delivery. FEBS Lett. 400:1997;233-237.
49. Liu Y., Mounkes L.C., Liggitt H.D., Brown C.S., Solodin I., Heath T.D., Debs R.J. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Biotechnology. 15:1997;167-173.
50. Templeton N.S., Lasic D.D., Frederik P.M., Strey H.H., Roberts D.D., Pavlakis G.N. Improved DNA/liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15:1997;647-652.
51. Gao X., Huang L. Cationic liposome-mediated gene transfer. Gene Ther. 2:1995;710-722.
52. Felgner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., Ramsey P., Martin M., Felgner P.L. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269:1994;2550-2561.
53. Zelphati O., Szoka F.C. Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 13:1996;1367-1372.
54. Gershon H., Ghirlando R., Guttman S.B., Minsky A. Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. Biochemistry. 32:1993;7143-7151.
55. Ross P.C., Hui S.W. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Ther. 6:1999;651-659.
56. Capaccioli S., Di Pasquale G., Mini E., Mazzei T., Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. [published erratum appears in Biochem. Biophys. Res. Commun. 200(3) (1994) 1769] Biochem. Biophys. Res. Commun. 197:1993;818-825.
57. Zhou X., Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim. Biophys. Acta. 1189:1994;195-203.
58. Zabner J., Fasbender A.J., Moninger T., Poellinger K.A., Welsh M.J. Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 270:1995;7-19007.
59. Bennett C.F., Chiang M.Y., Chan H., Shoemaker J.E., Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1992;1023-1033.
60. Bennett C.F., Mirejovsky D., Crooke R.M., Tsai Y.J., Felgner J., Sridhar C.N., Wheeler C.J., Felgner P.L. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. J Drug Targeting. 5:1998;149-162.
61. Farhood H., Serbina N., Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta. 1235:1995;289-295.
62. Zelphati O., Szoka F.C. Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA. 93:1996;11493-11498.
63. Szoka F.C. Jr., Xu Y., Zelphati O. How are nucleic acids released in cells from cationic lipid-nucleic acid complexes? Adv. Drug Deliv. Rev. 24:1997;291.
64. Thierry A.R., Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 20:1992;5691-5698.
65. Marcusson E.G., Bhat B., Manoharan M., Bennett C.F., Dean N.M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:1998;2016-2023.
66. Pontius B.W., Berg P. Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high probability binding domains in enhancing the kinetic of molecular assembly processes. Proc. Natl. Acad. Sci. USA. 88:1991;8237-8241.
67. Kronenwett R., Steidl U., Kirsch M., Sczakiel G., Haas R. Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood. 91:1998;852-862.
68. Radler J.O., Koltover I., Salditt T., Safinya C.R. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. (see comments) Science. 275:1997;810-814.
69. Chiang M.Y., Chan H., Zounes M.A., Freier S.M., Lima W.F., Bennett C.F. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266:1991;18162-18171.
70. Monia B.P., Johnston J.F., Ecker D.J., Zounes M.A., Lima W.F., Freier S.M. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267:1992;19954-19962.
71. Cioffi C.L., Garay M., Johnston J.F., McGraw K., Boggs R.T., Hreniuk D., Monia B.P. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol. Pharmacol. 51:1997;383-389.
72. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. (see comments) Nat. Med. 2:1996;668-675.
73. Ziegler A., Luedke G.H., Fabbro D., Altmann K.H., Stahel R.A., Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. (see comments) J. Natl. Cancer Inst. 89:1997;1027-1036.
74. Lebedeva I.V., Stein C.A. Bcl-xL-directed oligonucleotides in prostate and bladder carcinoma cell lines. Antisense Nucleic Acid Drug Dev. 9:1999;381-382.
75. Ackermann E.J., Taylor J.K., Narayana R., Bennett C.F. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J. Biol. Chem. 274:1999;11245-11252.
76. Tari A.M., Andreeff M., Kleine H.D., Lopez-Berestein G. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J. Mol. Med. 74:1996;623-628.
77. Motomura S., Motoji T., Takanashi M., Wang Y.H., Shiozaki H., Sugawara I., Aikawa E., Tomida A., Tsuruo T., Kanda N., Mizoguchi H. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood. 91:1998;3163-3171.
78. Hamilton S.E., Simmons C.G., Kathiriya I.S., Corey D.R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6:1999;343-351.
79. Zelphati O., Uyechi L.S., Barron L.G., Szoka F.C. Jr. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim. Biophys. Acta. 1390:1998;119-133.
80. Lewis J.G., Lin K.Y., Kothavale A., Flanagan W.M., Matteucci M.D., DePrince R.B., Mook R.A. Jr., Hendren R.W., Wagner R.W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA. 93:1996;3176-3181.
81. Meyer O., Kirpotin D., Hong K., Sternberg B., Park J.W., Woodle M.C., Papahadjopoulos D. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J. Biol. Chem. 273:1998;15621-15627.
82. Fresta M., Chillemi R., Spampinato S., Sciuto S., Puglisi G. Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. J. Pharm. Sci. 87:1998;616-625.
83. Vinogradov S.V., Bronich T.K., Kabanov A.V. Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug. Chem. 9:1998;805-812.
84. Guy-Caffey J.K., Bodepudi V., Bishop J.S., Jayaraman K., Chaudhary N. Novel polyaminolipids enhance the cellular uptake of oligonucleotides. J. Biol. Chem. 270:1995;31391-31396.
85. Roy S., Zhang K., Roth T., Vinogradov S., Kao R.S., Kabanov A. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat. Biotechnol. 17:1999;476-479.
86. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
87. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36.
88. Ansell S.M., Kojic L.D., Hankins J.S., Sekirov L., Boey A., Lee D.K., Bennett A.R., Klimuk S.K., Harasym T.O., Santos N.D., Semple S.C. Application of oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) lipid conjugates as steric barrier molecules in liposomal formulations. Bioconjug. Chem. 10:1999;653-666.
89. Gabizon A., Price D.C., Huberty J., Bresalier R.S., Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 50:1990;6371-6378.
90. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53:1993;3765-3770.
91. Bakker-Woudenberg I.A., Lokerse A.F., ten Kate M.T., Storm G. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim. Biophys. Acta. 1138:1992;318-326.
92. Mann M.J., Morishita R., Gibbons G.H., von der Leyen H.E., Dzau V.J. transfer into vascular smooth muscle using fusigenic Sendai virus (HVJ)-liposomes. Mol. Cell Biochem. 172:1997;3-12.
93. Fasbender A., Zabner J., Chillon M., Moninger T.O., Puga A.P., Davidson B.L., Welsh M.J. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J. Biol. Chem. 272:1997;6479-6489.
94. Waelti E.R., Gluck R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer. 77:1998;728-733.
95. Aoki M., Morishita R., Higaki J., Moriguchi A., Kida I., Hayashi S., Matsushita H., Kaneda Y., Ogihara T. In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. Biochem. Biophys. Res. Commun. 231:1997;540-545.
96. Slepushkin V.A., Simoes S., Dazin P., Newman M.S., Guo L.S., Pedroso de Lima M.C., Duzgunes N. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem. 272:1997;2382-2388.
97. Wang C.Y., Huang L. Plasmid DNA adsorbed to pH sensitive liposomes efficiently transforms target cells. Biochem. Biophys. Res. Commun. 147:1987;980-985.
98. Wang C.Y., Huang L. Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. Biochemistry. 28:1989;9508-9514.
99. Chu C.J., Dijkstra J., Lai M.Z., Hong K., Szoka F.C. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm. Res. 7:1990;824-834.
100. Duzgunes N., Pretzer E., Simoes S., Slepushkin V., Konopka K., Flasher D., de Lima M.C. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol. Membr. Biol. 16:1999;111-118.
101. Ropert C., Lavignon M., Dubernet C., Couvreur P., Malvy C. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. (published erratum appears in Biochem. Biophys. Res. Commun. 192(2) (1993) 982) Biochem. Biophys. Res. Commun. 183:1992;879-885.
102. Blume G., Cevc G., Crommelin M.D., Bakker-Woudenberg I.A., Kluft C., Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta. 1149:1993;180-184.
103. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta. 1234:1995;74-80.
104. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. [published erratum appears in Biochim. Biophys. Acta 1240(2) (1995) 285] Biochim. Biophys. Acta. 1237:1995;99-108.
105. Zelphati O., Imbach J.L., Signoret N., Zon G., Rayner B., Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 22:1994;4307-4314.
106. Zelphati O., Zon G., Leserman L. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res. Dev. 3:1993;323-338.
107. Zelphati O., Wagner E., Leserman L. Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. Antiviral Res. 25:1994;13-25.
108. Ma D.D., Wei A.Q. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk. Res. 20:1996;925-930.
109. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
110. Gottschalk S., Cristiano R.J., Smith L.C., Woo S.L. Folate receptor mediated DNA delivery into tumor cells: protosomal disruption results in enhanced gene expression. Gene Ther. 1:1994;185-191.
111. Lee R.J., Huang L. Folate targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene-transfer. J. Biol. Chem. 271:1996;8481-8487.
112. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3318-3322.
113. Bandyopadhyay P., Ma X., Linehan-Stieers C., Kren B.T., Steer C.J. Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides. J. Biol. Chem. 274:1999;10163-10172.
114. Chaudhuri G. Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. Biochem. Pharmacol. 53:1997;385-391.
115. de Lima M.C., Simoes S., Pires P., Gaspar R., Slepushkin V., Duzgunes N. Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. Mol. Membr. Biol. 16:1999;103-109.
116. Takle G.B., Thierry A.R., Flynn S.M., Peng B., White L., Devonish W., Galbraith R.A., Goldberg A.R., George S.T. Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). Antisense Nucleic Acid Drug Dev. 7:1997;177-185.
117. Alahari S.K., DeLong R., Fisher M.H., Dean N.M., Viliet P., Juliano R.L. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 286:1998;419-428.
118. DeLong R.K., Yoo H., Alahari S.K., Fisher M., Short S.M., Kang S.H., Kole R., Janout V., Regan S.L., Juliano R.L. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Res. 27:1999;3334-3341.
119. Bochot A., Fattal E., Gulik A., Couarraze G., Couvreur P. Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides. Pharm. Res. 15:1998;1364-1369.
120. Morris M.C., Vidal P., Chaloin L., Heitz F., Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25:1997;2730-2736.
121. Wu G.Y., Wu C.H. Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263:1988;14621-16624.
122. Findeis M.A., Wu C.H., Wu G.Y. Ligand-based carrier systems for delivery of DNA to hepatocytes. Methods Enzymol. 247:1994;341-351.
123. Fisher K.J., Wilson J.M. The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer. Biochem. J. 321:1997;49-58.
124. Perales J.C., Ferkol T., Beegen H., Ratnoff O.D., Hanson R.W. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. USA. 91:1994;4086-4090.
125. Wagner E., Cotton M., Foisner R., Birnstiel M.L. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc. Natl. Acad. Sci. USA. 88:1991;4255-4259.
126. Wagner E., Zenke M., Cotton M., Beug H., Birnstiel M.L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA. 87:1990;3410-3414.
127. Huckett B., Ariatti M., Hawtrey A.O. Evidence for targeted gene transfer by receptor-mediated endocytosis. Stable expression following insulin-directed entry of NEO into HepG2 cells. Biochem. Pharmacol. 40:1990;253-263.
128. Walker I., Irwin W.J., Akhtar S. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm. Res. 12:1995;1548-1553.
129. Despande D., Toledo-Velasquez D., Thakkar D., Liang W., Rojanasakul Y. Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in A549 cells. Pharm. Res. 13:1966;57-61.
130. Yin W., Cheng P.W. Lectin conjugate-directed gene transfer to airway epithelial cells. Biochem. Biophys. Res. Commun. 205:1994;826-833.
131. Ferkol T., Kaetzel C.S., Davis P.B. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 92:1993;2394-2400.
132. Ferkol T., Perales J.C., Mularo F., Hanson R.W. Receptor-mediated gene transfer into macrophages. Proc. Natl. Acad. Sci. USA. 93:1996;101-105.
133. Ginobbi P., Geiser T.A., Ombres D., Citro G. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res. 17:1997;29-35.
134. Mahato R.I., Takakura Y., Hashida M. Development of targeted delivery systems for nucleic acid drugs. J. Drug Targeting. 4:1997;337-357.
135. Fominaya J., Wels W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. J. Biol. Chem. 271:1996;10560-10568.
136. Ha H.C., Sirisoma N.S., Kuppusamy P., Zweier J.L., Woster P.M., Casero R.A. Jr. The natural polyamine spermine functions directly as a free radical scavenger. Proc. Natl. Acad. Sci. USA. 95:1998;11140-11145.
137. Pichon C., Freulon I., Midoux P., Mayer R., Monsigny M., Roche A.C. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. Antisense Nucleic Acid Drug Dev. 7:1997;335-343.
138. Parente R.A., Nadasdi L., Subbarao N.K., Szoka F.C. Jr. Association of a pH-sensitive peptide with membrane vesicles: role of amino acid sequence. Biochemistry. 29:1990;8713-8719.
139. Wyman T.B., Nicol F., Zelphati O., Scaria P.V., Plank C., Szoka F.C. Jr. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry. 36:1997;3008-3017.
140. Derossi D., Joliot A.H., Chassaing G., Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269:1994;10444-10450.
141. Derossi D., Chassaing G., Prochiantz A. Trojan peptides: the penetrating system for intracellular delivery. Trends Cell. Biol. 8:1998;84-87.
142. Morris M.C., Chaloin L., Mery J., Heitz F., Divita G. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res. 27:1999;3510-3517.
143. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA. 91:1994;664-668.
144. Chen L.L., Frankel A.D., Harder J.L., Fawell S., Barsoum J., Pepinsky B. Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin. Anal. Biochem. 227:1995;168-175.
145. Lin Y.Z., Yao S.Y., Veach R.A., Torgerson T.R., Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270:1995;14255-14258.
146. Dokka S., Toledo-Velasquez D., Shi X., Wang L., Rojanasakul Y. Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharm. Res. 14:1997;1759-1764.
147. Nielsen P.E., Egholm M., Berg R.H., Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 254:1991;1497-1500.
148. Hyrup B., Nielsen P.E. Peptide nucleic acids (PNA): synthesis, properties and potential applications. Bioorg. Med. Chem. 4:1996;5-23.
149. Good L., Nielsen P.E. Progress in developing PNA as a gene-targeted drug. Antisense Nucleic Acid Drug Dev. 7:1997;431-437.
150. Madon J., Blum H.E. Receptor-mediated delivery of hepatitis B virus DNA and antisense oligonucleotides to avian liver cells. Hepatology. 24:1996;474-481.
151. Rajur S.B., Roth C.M., Morgan J.R., Yarmush M.L. Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. Bioconjug. Chem. 8:1997;935-940.
152. Citro G., Szczylik C., Ginobbi P., Zupi G., Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer. 69:1994;463-467.
153. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA. 88:1991;5572-5576.
154. Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 89:1992;7031-7035.
155. Liu K., Ou J., Saku K., Jimi S., Via D.P., Sparrow J.T., Zhang B., Pownall H.J., Smith L.C., Arakawa K. Efficient nuclear delivery of antisense oligodeoxynucleotides and selective inhibition of CETP expression by apo E peptide in a human CETP-stably transfected CHO cell line. Arterioscler. Thromb. Vasc. Biol. 19:1999;2207-2213.
156. Vidal P., Morris M.C., Chaloin L., Heitz F., Divita G. New strategy for RNA vectorization in mammalian cells. Use of a peptide vector. C. R. Acad. Sci. III. 320:1997;279-287.
157. Bongartz J.-P., Aubertin A.-M., Milhaud P.G., Lebleu B. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 22:1994;4681-4688.
158. Demidov V.V., Potaman V.N., Frank-Kamenetskii M.D., Egholm M., Buchard O., Sonnichsen S.H., Nielsen P.E. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol. 48:1994;1310-1313.
159. Collas P., Husebye H., Alestrom P. The nuclear localization sequence of the SV40 T antigen promotes transgene uptake and expression in zebrafish embryo nuclei. Transgenic Res. 5:1996;451-458.
160. Sebestyen M.G., Ludtke J.J., Bassik M.C., Zhang G., Budker V., Lukhtanov E.A., Hagstrom J.E., Wolff J.A. DNA vector chemistry: the covalent attachment of signal peptides to plasmid DNA. Nat. Biotechnol. 16:1998;80-85.
161. Pooga M., Soomets U., Hallbrink M., Valkna A., Saar K., Rezaei K., Kahl U., Hao J.X., Xu X.J., Wiesenfeld-Hallin Z., Hokfelt T., Bartfai T., Langel U. Cell penetrating PNA constructs regulate galanine receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16:1998;857-861.
162. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271:1996;18188-18193.
163. Allinquant B., Hantraye P., Mailleux P., Moya K., Bouillot C., Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell. Biol. 128:1995;919-927.
164. Hughes J.A., Aronsohn A.I., Avrutskaya A.V., Juliano R.L. Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Pharm. Res. 13:1996;404-410.
165. Vidal P., Chaloin L., Heitz A., Van Mau N., Mery J., Divita G., Heitz F.
166. Chaloin L., Vidal P., Heitz A., Van Mau N., Mery J., Divita G., Heitz F. Conformations of primary amphipathic carrier peptides in membrane mimicking environments. Biochemistry. 36:1997;11179-11187.
167. Chaloin L., Vidal P., Lory P., Mery J., Lautredou N., Divita G., Heitz F. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochem. Biophys. Res. Commun. 243:1998;601-608.
168. Mann D.A., Frankel A.D. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10:1991;1733-1739.
169. Hughes J., Astriab A., Yoo H., Alahari S., Liang E., Sergeev D., Shaw B.R., Juliano R.L. In vitro transport and delivery of antisense oligonucleotides. Methods Enzymol. 313:1999;342-358.
170. Chen L.L., Frankel A.D., Harder J.L., Fawell S., Barsoum J., Pepinsky B. Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin. Anal. Biochem. 227:1995;168-175.
171. Pichon C., Arar K., Stewart A.J., Dodon M.D., Gazzolo L., Courtoy P.J., Mayer R., Monsigny M., Roche A.C. Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. Mol. Pharmacol. 51:1997;431-438.
172. Bachmann A.S., Surovoy A., Jung G., Moelling K. Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides. J. Mol. Med. 76:1998;126-132.
173. Meunier L., Mayer R., Monsigny M., Roche A.C. The nuclear export signal-dependent localization of oligonucleopeptides enhances the inhibition of the protein expression from a gene transcribed in cytosol. Nucleic Acids Res. 27:1999;2730-2736.
174. Milligan J.F., Matteucci M.D., Martin J.C. Current concepts in antisense drug design. J. Med. Chem. 36:1993;1923-1937.
175. Juliano R.L., Alahari S., Yoo H., Kole R., Cho M. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16:1999;494-502.
176. Mann M.J., Gibbons G.H., Hutchinson H., Poston R.S., Hoyt E.G., Robbins R.C., Dzau V.J. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc. Natl. Acad. Sci. USA. 96:1999;6411-6416.
177. Yasugi K., Nagasaki Y., Kato M., Kataoka K. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier. J Control. Release. 62:1999;89-100.
178. Liaw J., Aoyagi T., Kataoka K., Sakurai Y., Okano T. Visualization of PEO - PBLA-pyrene polymeric micelles by atomic force microscopy. Pharm. Res. 15:1998;1721-1726.
179. Vinogradov S., Batrakova E., Li S., Kabanov A. Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. Bioconjug. Chem. 10:1999;851-860.
180. Mumper R.J., Duguid J.G., Anwer K., Barron M.K., Nitta H., Rolland A.P. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm. Res. 13:1996;701-709.
181. Bertling W.M., Gareis M., Paspaleeva V., Zimmer A., Kreuter J., Nurnberg E., Harrer P. Use of liposomes, viral capsids, and nanoparticles as DNA carriers. Biotechnol. Appl. Biochem. 13:1991;390-405.
182. Chavany C., Le Doan T., Couvreur P., Puisieux F., Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm. Res. 9:1992;441-449.
183. Chavany C., Saison-Behmoaras T., Le Doan T., Puisieux F., Couvreur P., Helene C. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11:1994;1370-1378.
184. Zobel H.P., Kreuter J., Werner D., Noe C.R., Kumel G., Zimmer A. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7:1997;483-493.
185. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., Saison-Behmoaras T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA. 91:1994;10460-10464.
186. Godard G., Boutorine A.S., Saison-Behmoaras E., Helene C. Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. Eur. J. Biochem. 232:1995;404-410.
187. Fattal E., Vauthier C., Aynie I., Nakada Y., Lambert G., Malvy C., Couvreur P. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Control. Release. 53:1998;137-143.
188. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods. 18:1999;286-295.
189. Berton M., Benimetskaya L., Allemann E., Stein C.A., Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur. J. Pharm. Biopharm. 47:1999;119-123.
190. Aynie I., Vauthier C., Chacun H., Fattal E., Couvreur P. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:1999;301-312.
191. Haensler J., Szoka F.C. Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem. 4:1993;372-379.
192. Delong R., Stephenson K., Loftus T., Fisher M., Alahari S., Nolting A., Juliano R.L. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86:1997;762-764.
193. Frechet J.M. Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. Science. 263:1994;1710-1715.
194. Zimmerman S.C., Zeng F., Reichert D.E., Kolotuchin S.V. Self-assembling dendrimers. (see comments) Science. 271:1996;1095-1098.
195. Roberts J.C., Adams Y.E., Tomalia D., Mercer-Smith J.A., Lavallee D.K. Using starburst dendrimers as linker molecules to radiolabel antibodies. Bioconjug. Chem. 1:1990;305-308.
196. Bielinska A., Kukowska-Latallo J.F., Johnson J., Tomalia D.A., Baker J.R. Jr. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:1996;2176-2182.
197. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., Tomalia D.A., Baker J.R. Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. USA. 93:1996;4897-4902.
198. Yoo H., Sazani P., Juliano R.L. PMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm. Res. 16:1999;1799-1802.
199. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18:1997;12-18.
200. Bennett C.F., Kornburst D., Henry S., Stecker K., Howard R., Coper S., Dutson S., Hall W., Jacoby H.I. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium induced colitis in mice. J. Pharm. Exp. Ther. 280:1997;988-1000.
201. Gray G.D., Hernandez O.M., Hebel D., Root M., Pow-Sang J.M., Wickstrom E. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res. 53:1993;577-580.
202. Wickstrom E., Bacon T.A., Wickstrom E.L. Down-regulation of c-MYC antigen expression in lymphocytes of Eμ-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res. 52:1992;6741-6745.
203. Ratajczak M.Z., Kant J.A., Luger S.M., Hijia N., Zhang J., Zon G., Gewirtz A.M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 89:1992;11823-11827.
204. Offensperger W.B., Offensperger S., Blum H.E. Antisense therapy of hepatitis B virus infection. Mol. Biotechnol. 9:1998;161-170.
205. Moriya K., Matsukura M., Kurokawa K., Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochem. Biophys. Res. Commun. 218:1996;217-223.
206. Bijsterbosch M.K., Manoharan M., Rump E.T., De Vrueh R.L.A., van Veghel R., Tivel K.L., Biessen E.A.L., Bennett C.F., Dan Cook P., van Berkel T.J.C. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. 25:1997;3290-3296.
207. Biessen E.A.L., Vietsch H., Kuiper J., Bijsterbosch M.K., van Berkel T.J.C. Liver uptake of phosphodiester oligonucleotides is mediated by scavenger receptors. Mol. Pharmacol. 53:1998;262-269.
208. Driver S.E., Robinson G.S., Flanagan J., Shen W., Smith L.E.H., Thomas D.W., Roberts P.C. Oligonucleotide-based inhibition of embryonic gene expression. Nat. Biotechnol. 17:1999;1184-1187.
209. Tyler B.M., McCormick D.J., Hoshall C.V., Douglas C.L., Jansen K., Lacy B.W., Cusack B., Richelson E. Specific gene blockage shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Lett. 421:1998;280-284.
210. Tyler B.M., Jansen K., McCormick D.J., Douglas C.L., Boules M., Stewart J.A., Zhao L., Lacy B., Cusack B., Fauq A., Richelson E. Peptide nucleic acids targeted to neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc. Natl. Acad. Sci. USA. 96:1999;7053-7058.
211. Xin W., Wang J.H. Treatment of duck hepatitis B virus by antisense poly-2′-O-(2,4-dinitrophenyl)-oligoribonucleotides. Antisense Nucleic Acid Drug Dev. 8:1998;459-468.
212. Crooke S.T., Bennett C.F. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. 36:1996;107-129.
213. Akhtar S. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. (Editorial) J. Drug Targeting. 5:1998;225-234.
214. Juliano R.L., Akhtar S. Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res. Dev. 2:1992;165-176.
215. Tari A., Khodadadian M., Ellerson D., Deisseroth A., Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk. Lymphoma. 21:1996;93-97.
216. Gutierrez-Puente Y., Tari A.M., Stephens C., Rosenblum M., Guerra R.T., Lopez-Berestein G. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J. Pharmacol. Exp. Ther. 291:1999;865-869.
217. Klimuk S.K., Semple S.C., Scherrer P., Hope M.J. Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes. Biochim. Biophys. Acta. 1417:1999;191-201.
218. Nomura T., Yamashita F., Takakura Y., Hashida M. Pharmakokinetic analysis of various lipid carrier systems after intratumoral injection in tissue isolated tumors. Proc. Int. Symp. Control. Release Bioact. Mater. 22:1995;420-421.
219. Stewart M.J., Plautz G.E., Del-Buono L., Yang Z.Y., Gao L., Huang L., Nabel E.G., Nabel J.G. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum. Gene Ther. 3:1992;267-275.
220. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharm. Rev. 51:1999;691-743.
221. Klimuk S.K., Semple S.C., Nahirney P.N., Mullen M.C., Bennett C.F., Scherrer P., Hope M.J. Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligonucleotide in an acute model of contact hypersensitivity. J. Pharmacol. Exp. Ther. 292:2000;480-488.
222. Wielbo D., Shi N., Sernia C. Antisense inhibition of angiotensin in hepatoma cell culture is enhanced by cationic liposome delivery. Biochem. Biophys. Res. Commun. 232:1997;794-799.
223. Marzo A.L., Fitzpatrick D.R., Robinson B.W., Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res. 57:1997;3200-3207.
224. Matsuno A., Nagashima T., Katayama H., Tamura A. In vitro and in vivo delivery of antisense oligonucleotides using lipofection: application of antisense technique to growth suppression of experimental glioma. Methods Enzymol. 313:1999;359-372.
225. Gokhale P.C., Soldatenkov V., Wang F.H., Rahman A., Dritschilo A., Kasid U. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther. 4:1997;1289-1299.
226. Baba M., Iishi H., Tatsuta M. In vivo electrophoretic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. Int. J. Cancer. 85:2000;260-266.
227. Soni P.N., Brown D., Sffie R., Savage K., Moore D., Gregoriadis G., Dusheiko G.M. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligonucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology. 28:1998;1402-1410.
228. Litzinger D.C., Brown J.M., Wala I., Kaufman S.A., Van G.Y., Farrell C.L., Collins D. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta. 1281:1996;139-149.
229. Thierry A.R., Rabinovich P., Peng B., Mahan L.C., Bryant J.L., Gallo R.C. Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA. Gene Ther. 4:1997;226-237.
230. Yu R.Z., Geary R.S., Leeds J.M., Watanabe T., Fitchett J.R., Matson J.E., Mehto R., Hardee G.R., Templin M.V., Huang K., Newman M.S., Quinn Y., Uster P., Zhu G., Working P.K., Horner M., Nelson J., Levin A.A. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes. Pharm. Res. 16:1999;1309-1315.
231. Morishita R., Gibbons G.H., Kaneda Y., Ogihara T., Dzau V.J. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 149:1994;13-19.
232. Nakamura N., Timmermann S.A., Hart D.A., Kaneda Y., Shrive N.G., Shino K., Ochi T., Frank C.B. A comparison of in vivo gene delivery methods for antisense therapy in ligament healing. Gene Ther. 5:1998;1455-1461.
233. Dzau V.J., Mann M.J., Morishita R., Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc. Natl. Acad. Sci. USA. 93:1996;11421-11425.
234. Hangai M., Tanihara H., Honda Y., Kaneda Y. In vivo delivery of phosphorothioate oligonucleotides into murine retina. Arch. Ophtalmol. 116:1998;342-348.
235. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. Single intramural delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA. 90:1993;8474-8478.
236. Smith R.D. The pathobiology of HIV infection. A review. Arch. Pathol. Lab. Med. 114:1990;235-239.
237. Nabel G.J., Nabel E.G., Yang Z.Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA. 90:1993;11307-11311.
238. Mizuta T., Fudjiwara M., Hatta T., Abe T., Miyano-Kurosaki N., Shigeta S., Yokota T., Akaku H. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nat. Biotechnol. 17:1999;583-587.
239. Roy S., Zhang K., Roth T., Vinogradov S., Kao R.S., Kabanov A. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat. Biotechnol. 17:1999;476-479.
240. Chemin I., Moradpour D., Wieland S., Offensperger W.B., Walter E., Behr J.P., Blum H.E. Liver-directed gene transfer: a linear polyethylenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo. J. Viral Hepatol. 5:1998;369-375.
241. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Sherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA. 92:(16):1995;7297-7301.
242. Schwab G., Duroux I., Chavany C., Helene C., Saison-Behmoaras E. An approach for new anticancer drugs: oncogene-targeted antisense DNA. Ann. Oncol. 5:(Suppl. 4):1994;55-58.
243. Carmichael E.P., Chiou H.C., Findeis M.A., Spitalny G.L., Merwin J.R. Targeted delivery of anti-hepatitis B antisense oligonucleotides. Akhtar S. Delivery Strategies for Antisense Oligonucleotide Therapeutics. 1995;267-282 CRC Press, New York.
244. Lu X.M., Fischman A.J., Jyawook S.L., Hendricks K., Tompkins R.G., Yarmush M.L. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J. Nucl. Med. 35:1994;269-275.
245. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H., Kamada M., Mizushima A. Effect of antisense oligonucleotides against cholesterol ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:1998;5033-5036.
246. Mahato R.I., Takemura S., Takakira Y., Hashida M. Physico-chemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine) in mice. Biochem. Pharmacol. 53:1997;887-895.
247. Biessen E.A.L., Vietsch H., Rump E.T., Fluiter K., Kuiper J., Bijsterbosch M.K., Van Berkel T.J.C. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem. J. 340:1999;783-792.
248. Duff R.J., Deamond S.F., Roby C., Zhou Y., Ts'o P.O.P. Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates. Methods Enzymol. 313:1999;297-321.
249. 32P]-labeled oligodeoxynucleoside methylphosphonate-neoglycopeptide conjugate, (YEE(ah-GalNAc)3)-SMCC-AET-pUmpT7, in the mouse. Antisense Nucleic Acid Drug Dev. 7:1997;141-149.
250. 32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. Drug Metab. Dispos. 23:1995;55-59.
251. 3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol. Exp. Ther. 276:1996;206-211.
252. Pardridge W.M., Boado R.J., Kang Y.-S. Vector-mediated delivery of a polyamide ('peptide') nucleic acid s analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA. 92:1995;5592-5596.
253. Boado R.J., Tsukamoto H., Pardridge W.M. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J. Pharm. Sci. 87:1998;1308-1315.
254. Penichet M.L., Kang Y.S., Pardridge W.M., Morrison S.L., Shin S.U. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J. Immunol. 163:1999;4421-4426.
255. Szoka F.C. Jr., Xu Y., Zelphati O. How are nucleic acids released in cells from cationic lipid-nucleic acid complexes? J. Liposome Res. 6:1996;567-587.